Carolina Ionete to Multiple Sclerosis, Relapsing-Remitting
This is a "connection" page, showing publications Carolina Ionete has written about Multiple Sclerosis, Relapsing-Remitting.
Connection Strength
1.823
-
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H. Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2025 May 15; 392(19):1893-1904.
Score: 0.235
-
Wilken J, Traboulsee A, Nelson F, Ionete C, Kolind S, Fratto T, Kane R, Gandhi R, Rawlings AM, Roesch N, Ozog MA, DeLuca J. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results. Mult Scler Relat Disord. 2023 May; 73:104677.
Score: 0.204
-
Sato S, Buonaccorsi J, Miehm JD, Lim J, Rajala C, Khalighinejad F, Ionete C, Kent JA, van Emmerik REA. Non-ambulatory measures of lower extremity sensorimotor function are associated with walking function in Multiple Sclerosis. Mult Scler Relat Disord. 2021 Aug; 53:103051.
Score: 0.180
-
Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintor? M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Mult Scler Relat Disord. 2021 Apr; 49:102717.
Score: 0.174
-
Herman JA, Khalighinejad F, York K, Radu I, Berrios Morales I, Ionete C, Hemond CC. A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis. Mult Scler Relat Disord. 2021 Jan; 47:102619.
Score: 0.173
-
Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fern?ndez ?, Ionete C, Massacesi L, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov; 267(11):3343-3353.
Score: 0.168
-
Sato S, Lim J, Miehm JD, Buonaccorsi J, Rajala C, Khalighinejad F, Ionete C, Kent JA, van Emmerik REA. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2020 Jun; 41:102031.
Score: 0.165
-
Herranz E, Giann? C, Louapre C, Treaba CA, Govindarajan ST, Ouellette R, Loggia ML, Sloane JA, Madigan N, Izquierdo-Garcia D, Ward N, Mangeat G, Granberg T, Klawiter EC, Catana C, Hooker JM, Taylor N, Ionete C, Kinkel RP, Mainero C. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol. 2016 Nov; 80(5):776-790.
Score: 0.131
-
Rounds WH, Salinas EA, Wilks TB, Levin MK, Ligocki AJ, Ionete C, Pardo CA, Vernino S, Greenberg BM, Bigwood DW, Eastman EM, Cowell LG, Monson NL. MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing. Gene. 2015 Nov 10; 572(2):191-7.
Score: 0.119
-
Cachia D, Izzy S, Berriosmorales I, Ionete C. Drug-induced thrombocytopenia secondary to natalizumab treatment. BMJ Case Rep. 2014 May 30; 2014.
Score: 0.111
-
Tanasescu R, Ionete C, Chou IJ, Constantinescu CS. Advances in the treatment of relapsing-remitting multiple sclerosis. Biomed J. 2014 Mar-Apr; 37(2):41-9.
Score: 0.109
-
Herranz E, Treaba CA, Barletta VT, Mehndiratta A, Ouellette R, Sloane JA, Ionete C, Babu S, Mastantuono M, Magon S, Loggia ML, Makary MM, Hooker JM, Catana C, Kinkel RP, Nicholas R, Klawiter EC, Magliozzi R, Mainero C. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis. Brain. 2024 Jul 05; 147(7):2566-2578.
Score: 0.056